Amira Qumseya

Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group

S. Donaldson, D. Rodeberg, D. Hawkins, 2022, Pediatric blood & cancer.

Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.

D. Hawkins, E. Rudzinski, R. Venkatramani, 2024, The Lancet. Oncology.

Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

D. Rodeberg, W. Xue, R. Venkatramani, 2023, Pediatric blood & cancer.

Outcome of patients with relapsed or refractory nonrhabdomyosarcoma soft tissue sarcomas enrolled in phase 2 cooperative group clinical trials: A report from the Children’s Oncology Group

R. Venkatramani, A. Weiss, Sapna Oberoi, 2024, Cancer.